Oral Oncology
Volume 37, Issue 1 , Pages 1-16 , January 2001

A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma

  • S.S. Prime

      Affiliations

    • Department of Oral and Dental Science, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-117-928-4304; fax: +44-117-928-4428
    • ,
  • N.S. Thakker

      Affiliations

    • University Department of Medical Genetics, St Mary's Hospital, Manchester M13 0JH, UK
    • ,
  • M. Pring

      Affiliations

    • Department of Oral and Dental Science, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY, UK
    • ,
  • P.G. Guest

      Affiliations

    • Department of Oral and Dental Science, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY, UK
    • ,
  • I.C. Paterson

      Affiliations

    • Department of Oral and Dental Science, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY, UK

Received 15 March 2000 ,Accepted 27 March 2000.

References 

  1. Kinzler KW, Vogelstein B. Cancer-susceptibility genes, gatekeepers and caretakers. Nature. 1997;386:761–763
  2. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386:804–810
  3. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al.  Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265–275
  4. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science. 1998;280:1036–1037
  5. Knudson AG. Hereditary cancer, two hits revisited. Journal of Cancer Research and Clinical Oncology. 1996;122:135–140
  6. Ward P, Packman S, Loughman W, Sparkes M, Sparkes R, McMahon A, et al.  Location of the retinoblastoma susceptibility gene(s) and the human esterase D locus. Journal of Medical Genetics. 1984;21:92–95
  7. Li FP, Fraumeni JF. Soft tissue sarcomas, breast cancer and other neoplasms. A familial cancer syndrome?. Annals of Internal Medicine. 1969;71:747–752
  8. Prives C, Hall PA. The P53 pathway. Journal of Pathology. 1999;187:112–126
  9. Haber DA. Wilms tumor. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 409–421
  10. Preston FW, Walsh WS, Clark TH. Cutaneous neurofibromatosis (von Recklinghausen's disease). Clinical manifestations and incidence of sarcoma in sixty one male patients. Archives of Surgery. 1952;64:813
  11. Gutmann DH, Collins FS. Neurofibromatosis Type I. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 423–442
  12. MacCollin M, Gusella J. Neurofibromatosis type 2. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 443–453
  13. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72:791–800
  14. Glen GM, Choyke PL, Zbar B, Linehan WM. Von Hippel-Lindau disease. Clinical review and molecular genetics. In:  Anderson EE editors. Problems in urologic surgery, benign and malignant tumours of the kidney. Philadelphia Lippincott; 1990;p. 312–353
  15. Richards FM, Maher ER, Latif F, Phipps ME, Tory K, Lush M, et al.  Detailed genetic mapping of von Hippel-Lindau disease tumour suppressor gene. Journal of Medical Genetics. 1993;30:104–107
  16. Marx S. Multiple endocrine neoplasia type I. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 489–506
  17. Thakker RV, Ponder BAJ. Multiple endocrine neoplasia. Baillieres Clinical Endocrinology and Metabolism. 1988;2:1031–1067
  18. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 — International RET mutation consortium analysis. Journal of the American Medical Association. 1996;276:1575–1579
  19. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, et al.  Characterisation of a multi component receptor for GDNF. Nature. 1996;382:80–83
  20. Eng C, Parsons R. Cowden syndrome. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 519–525
  21. Jacoby RF, Schlack S, Cole CE, Skarbek M, Harris C, Meisner LF. A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology. 1997;112:1398–1403
  22. Kinzler KW, Vogelstein B. Colorectal tumours. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 565–587
  23. Couch FJ, Weber BL. Breast cancer. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 537–563
  24. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al.  Identification of FAP locus genes from chromosome 5q21. Science. 1991;253:661–665
  25. Powell SM, Petersen GM, Krush AJ, Booker S, Jen J, Giardiello FM, et al.  Molecular diagnosis of familial adenomatous polyposis. New England Journal of Medicine. 1993;329:1982–1987
  26. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al.  Somatic mutations of the APC gene in colorectal tumours, mutation cluster region in the APC gene. Human Molecular Genetics. 1992;1:229–233
  27. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proceedings of the National Academy of Science USA. 1996;93:7950–7954
  28. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al.  Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992;256:668–670
  29. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992;258:1148–1152
  30. Kamb A. Human melanoma genetics. Journal of Investigative Dermatology Symposium Proceedings. 1996;1:177–182
  31. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, et al.  Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Human Genetics. 1995;4:1845–1852
  32. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al.  Mutations of the human homolog of Drosophila patched in the naevoid basal cell carcinoma syndrome. Cell. 1996;85:841–851
  33. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al.  Human homolog of patched, a candidate gene for the basal cell naevus syndrome. Science. 1996;272:1668–1671
  34. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al.  The role of human homolog of Drosophila patched in sporadic basal cell carcinomas. Nature Genetics. 1996;14:78–81
  35. Ferguson-Smith J. Multiple primary, self-healing epitheliomata of the skin. British Journal of Dermatology. 1948;60:315–317
  36. Goudie DR, Yuille MA, Leversha MA, Furlong RA, Carter NP, Lush MJ, et al.  Multiple self-healing squamous epitheliomata (ESS1) mapped to chromosome 9q22-q31 in families with common ancestry. Nature Genetics. 1993;3:165–169
  37. Richards FM, Goudie DR, Cooper WN, Jene Q, Barroso I, Wicking C, et al.  Mapping of the multiple self-healing squamous epithelioma (MSSE) gene and investigation of xeroderma pigmentosum group A (XPA) and PATCHED (PTCH) as candidate genes. Human Genetics. 1997;101:317–322
  38. Young NS, Alter BP. Dyskeratosis congenital. In:  Young NS,  Alter BP editor. Aplastic anaemia. Acquired and inherited. Philadelphia; WB Saunders; 1994;p. 325–339
  39. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al.  X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nature Genetics. 1998;19:32–38
  40. Field EA, Ellis A, Friedmann PS, Leigh IM, Field JK. Oral tylosis: a reappraisal. Oral Oncology. 1997;33:55–57
  41. Brehm A, Miska E, Reid J, Bannister AM, Kouzarides T. The cell cycle-regulating transcription factors E2F-RB. British Journal of Cancer. 1999;80:38–41
  42. Nevins JR. E2F, a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258:424–429
  43. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–330
  44. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Advances in Cancer Research. 1996;68:67–108
  45. Hsieh JK, Chan FS, O'Connor DH, Mittnacht S, Zhong S, Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Molecular Cell. 1999;3:181–193
  46. Yap DB, Hsieh J-K, Chan FSG, Lu X. mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene. 1999;18:7681–7689
  47. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5–8
  48. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al.  p14/ARF links the tumour suppressors RB and p53. Nature. 1998;395:124–125
  49. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblasoma. British Journal of Cancer. 1986;53:661–671
  50. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al.  Mortality from second tumours among long term survivors of retinoblastoma. Journal of the National Cancer Institute. 1993;85:1112–1128
  51. Abramson DH, Ellsworth RM, Kichin FD, Tung G. Second non-ocular tumours in retinoblastoma survivors. Are they radiation-induced?. Opthalmology. 1984;91:1351–1355
  52. Yoo GH, Xu HJ, Brennan JA, Westra W, Hruban RH, Koch W, et al.  Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Research. 1994;54:4603–4606
  53. Yokoyama J, Shiga K, Sasano H, Suzuki M, Takasaka T. Abnormalities and the implication of retinoblastoma locus and its protein product in head and neck cancers. Anticancer Research. 1996;16:641–644
  54. Pavelic ZP, Lasmar M, Pavelic L, Sorensen C, Stambrook PJ, Zimmermann N, et al.  Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Oral Oncology Eur J Cancer. 1996;32B:347–351
  55. Sakata K. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine. 1996;25:302–307
  56. Pande P, Mathur M, Shukla NK, Ralhan R. pRB and p16 protein alterations in human oral tumorigenesis. Oral Oncology. 1998;34:396–403
  57. El-Naggar AK, Lai S, Clayman GL, Zhou JH, Tucker SA, Myers J, et al.  Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma, biological and clinical implications. Hum Pathology. 1999;30:1013–1018
  58. Okami K, Reed AL, Cairns P, Koch WM, Westra WH, Wehage S, et al.  Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene. 1999;18:3541–3545
  59. Malkin D. The Li Fraumeni syndrome. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 393–407
  60. Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. Multiple primary cancersin families with Li Fraumeni syndrome. Journal of the National Cancer Institute. 1998;90:606–611
  61. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. Journal of the National Cancer Institute. 1987;79:1213–1220
  62. Hartley AL, Birch JM, Kelsey AM, Marsden HB, Harris M, Teare MD. Are germ cell tumours part of the Li Fraumeni cancer family syndrome?. Cancer Genetics and Cytogenetics. 1989;42:221–226
  63. Garber JE, Liepman MK, Gelles EJ, Corson JM, Antman KH. Melanoma and soft tissue sarcoma in seven patients. Cancer. 1990;66:2432–2434
  64. Gardner GM, Steiniger JR. Family cancer syndrome: a study of the kindred of a man with osteogenic sarcoma of the mandible. Laryngoscope. 1990;100:1259–1263
  65. Rowley H, Sherrington P, Helliwell TR, Kinsella AM, Jones AS. p53 expression and p53 gene mutation in oral cancer and dysplasia. Otolaryngology and Head and Neck Surgery. 1998;118:115–123
  66. Qin GZ, Park JY, Chen SY, Lazarus P. A high prevalence of p53 mutations in pre-malignant oral erythroplakia. International Journal of Cancer. 1999;80:345–348
  67. Gallo O, Sardi I, Pepe G, Franchi A, Attanasio M, Giusti B, et al.  Multiple primary tumors of the upper aerodigestive tract: is there a role for constitutional mutations in the p53 gene?. International Journal of Cancer. 1999;82:180–186
  68. Agarwal S, Mathur M, Srivastava A, Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions, potential prognostic implications. Oral Oncology. 1999;35:209–216
  69. Paterson IC, Eveson JW, Prime SS. Molecular changes in oral cancer may reflect aetiology and ethnic origin. Oral Oncology, European Journal of Cancer. 1996;32B:150–153
  70. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al.  High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Research. 1996;56:3630–3633
  71. Hiranuma H, Jikko A, Maeda T, Matumura S, Murakami S, Fukuda Y, et al.  An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. Oral Oncology. 1998;34:513–518
  72. Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, et al.  p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathology. 1998;184:360–368
  73. Kaur J, Srivastava A, Ralhan R. Prognostic significance of p53 protein overexpression in betel- and tobacco-related oral oncogenesis. International Journal of Cancer. 1998;79:370–375
  74. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, et al.  p53 expression: predicting recurrence and second primary tumours in head and neck squamous cell carcinoma. Journal of the National Cancer Institute. 1996;88:519–529
  75. Bryd R, Levine A. Late treatment of Wilms' tumor. In:  Pochedley C,  Baum ES editor. Clinical and biological manifestations, vol. 19. New York: Elsevier; 1984;p. 347–354
  76. Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M. Three discrete regions of deletion at 3p in head and neck cancers. Cancer Research. 1993;53:5775–5779
  77. Wu C-L, Sloan P, Read AP, Harris R, Thakker N. Deletion mapping of the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Research. 1999;54:6484–6488
  78. Field JK, Tsiriyotis C, Zoumpourlis V, Howard P, Spandidos DA, Jones AS. Allele loss on chromosome 3 in squamous cell carcinoma of the head and neck correlates with poor clinical prognostic indicators. International Journal of Oncology. 1994;4:543–549
  79. Partridge M, Kiguwa S, Langdon JD. Frequent deletion of chromosome 3p in oral squamous cell carcinoma. Oral Oncology, European Journal of Cancer. 1994;30B:248–251
  80. Uzawa N, Yoshida MA, Oshimura M, Ikeuchi T. Suppression of tumorigenicity in three different cell lines of human oral squamous cell carcinomas by introduction of chromosome 3p via microcell-mediated chromosome transfer. Oncogene. 1995;11:1997–2004
  81. Uzawa N, Yoshida MA, Hosoe S, Oshimura M, Amagasa T, Ikeuchi T. Functional evidence for involvement of multiple putative tumor suppressor genes on the short arm of chromosome 3 in human oral squamous cell carcinogenesis. Cancer Genetics and Cytogenetics. 1998;107:125–131
  82. Partridge M, Emilion G, Pateromichelakis S, Philips E, Langdon J. Location of candidate tumour suppressor gene loci at chromosome 3p, 8p and 9p for oral squamous cell carcinomas. International Journal of Cancer. 1999;83:318–325
  83. Blons H, Radicella JP, Laccourreye O, Brasnu D, Beaune P, Boiteux S, et al.  Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-Oxoguanine DNA Glycosylase 1 gene in head and neck cancer. Molecular Carcinogenesis. 1999;26:254–260
  84. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, et al.  FHIT gene alterations in head and neck squamous cell carcinomas. Proceedings of the National Academy of Sciences USA. 1996;93:9770–9775
  85. Pateromichelakis S, Lee G, Langdon JD, Partridge M. The FHIT gene in oral squamous cell carcinoma: allelic imbalance is frequent but cDNA aberrations are uncommon. Oral Oncology. 2000;36:180–188
  86. van Heerden WF, Swart TJ, van Heerden MB, van Rensburg EJ, Engelbrecht S, Dreyer L, et al.  Immunohistochemical evaluation of Fhit protein expression in oral squamous cell carcinomas. Journal of Oral Pathology and Medicine. 1999;28:433–437
  87. Wang D, Song H, Evans JA, Lang JC, Schuller DE, Weghorst CM. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis. 1997;18:2285–2290
  88. Paterson, I.C., Matthews, J.B., Fahey, M., Parkinson, E.K., Prime, S.S. Decreased expression of TGF-β cell surface receptors during progression of human oral squamous cell carcinoma. Journal of Pathology (submitted).
  89. Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Lee G, Phillips E, et al.  The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer. British Journal of Cancer. 1999;79:1821–1827
  90. Muller D, Millon R, Lidereau R, Engelmann A, Bronner G, Flesch H, et al.  Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. Oral Oncology, European Journal of Cancer. 1994;30B:113–120
  91. Koreth J, Bakkenist CJ, McGee JOD. Chromosomes, 11q and cancer, a review. Journal of Pathology. 1999;187:28–38
  92. Berenson JR, Yang J, Mickel RA. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. Oncogene. 1989;4:1111–1116
  93. Somers KD, Cartright SL, Schechter GL. Amplification of the int-2 gene in human head and neck squamous cell carcinoma. Oncogene. 1990;5:915–920
  94. Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD. Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene. 1996;12:31–35
  95. Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K, et al.  Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics. 1999;9:165–169
  96. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S, et al.  Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. International Journal of Cancer. 1999;81:44–48
  97. Xu J, Gimenez-Conti IB, Cunningham JE, Collet AM, Luna MA, Lanfranchi HE, et al.  Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer. 1998;83:204–212
  98. Sartor M, Steingrimsdottir H, Elamin F, Gaken J, Warnakulasuriya S, Partridge M, et al.  Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. British Journal of Cancer. 1999;80:79–86
  99. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, et al.  Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clinical Cancer Research. 1999;5:2810–2819
  100. Gaffey MJ, Iezzoni JC, Meredith SD, Boyd JC, Stoler MH, Weiss LM, et al.  Cyclin D1 (PRAD1/CCND1) and glutathione S transferase gene expression in head and neck squamous cell carcinoma. Human Pathology. 1995;26:1221–1226
  101. Kuo MY, Lin CY, Hahn LJ, Cheng SJ, Chiang CP. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. Journal of Oral Pathology and Medicine. 1999;28:165–169
  102. Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, et al.  Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. International Journal of Cancer. 1998;77:684–688
  103. Chen Q, Samaranayake L, Zhou H, Xiao L. Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma. Oral Oncology. 2000;36:95–99
  104. Teare MD, Wallace SA, Harris M, Howell A, Birch JM. Cancer experience in the relatives of an unselected series of breast cancer patients. British Journal of Cancer. 1994;70:102–111
  105. Auclair PL, Ellis GL, Gnepp DR, Wenig BM, Janney CG. Salivary gland neoplasms: general considerations. In:  Ellis GL,  Auclair PL,  Gnepp DR editor. Surgical pathology of the salivary glands. Philadelphia: WB Saunders Company; 1991;p. 135–164
  106. Hamel N, Manning A, Black MJ, Tonin PN, Foulkes WD. An absence of founder BRCA 2 mutations in individuals with squamous cell carcinoma of the head and neck. International Journal of Cancer. 1999;83:803–804
  107. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, et al.  Association of the APC gene product with β-catenin. Science. 1993;262:1731–1734
  108. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumour suppressor protein with catenins. Science. 1993;262:1734–1737
  109. Giardiello FM. Gastrointestinal polyposis syndromes and hereditary nonpolyposis colorectal cancer. In:  Rustgi AK editors. Gastrointestinal cancers, biology, diagnosis and therapy. Philidelphia: Lippincott-Raven; 1995;p. 367–377
  110. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al.  The molecular basis of Turcot's syndrome. New England Journal of Medicine. 1995;332:839–847
  111. Uzawa K, Yoshida H, Suzuki H, Tanzawa H, Shimazaki J, Seino S, et al.  Abnormalities of the adenomatous polyposis coli gene in human oral squamous cell carcinoma. International Journal of Cancer. 1994;58:814–817
  112. Mao E-J, Oda D, Haigh WG, Beckmann AM. Loss of the adenomatous polyposis coli gene and human papillomavirus infection in oral carcinogenesis. Oral Oncology, European Journal of Cancer. 1996;32:260–263
  113. Mao EJ, Schwartz SM, Daling JR, Beckmann AM. Loss of heterozygosity at 5q21-22 (adenomatous polyposis coli gene region) in oral squamous cell carcinoma is common and correlated with advanced disease. Journal of Oral Pathology and Medicine. 1998;27:297–302
  114. Huang JS, Chiang CP, Kok SH, Kuo YS, Kuo MY. Loss of heterozygosity of APC and MCC genes in oral squamous cell carcinoma in Taiwan. Journal of Oral Pathology and Medicine. 1997;26:322–326
  115. Ruas M, Peters G. The P16INK4A/CDKN2A tumour supporessor and its relatives. Biochimicha et Biophysicha Acta. 1998;1378:F115–F177
  116. Loughran O, Malliri A, Owens D, Gallimore PH, Stanley MA, Ozanne B, et al.  Association of CDKN2A/p16INK4A with human head and heck keratinocyte replicative senescence, relationship of dysfunction to immortality and neoplasia. Oncogene. 1996;13:561–568
  117. Wu CL, Roz L, McKown S, Sloan P, Read AP, Holland S, et al.  DNA studies understimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas. Genes, Chromosomes and Cancer. 1999;25:16–25
  118. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenital. Nature. 1999;402:551–555
  119. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum, cutaneous, ocular and neurological abnormalities in 830 published cases. Archives of Dermatology. 1987;123:241–250
  120. Cleaver JE, Kraemer KH. Xeroderma pigmentosum and Cockayne syndrome. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease, 7th ed. New York: McGraw Hill; 1995;p. 4393–4523
  121. Gatti RA. Ataxia-telangiectasia. Neurofibromatosis type I. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 275–300
  122. Lange E, Borreson A-L, Chen XG, Chessa L, Chiplunkar S, Concannon P, et al.  Localisation af an ataxia-telangiectasia gene to a 500 kb interval on chromosome 11q23.1. Linkage analysis of 176 families in an international consortium. American Journal of Human Genetics. 1995;57:112–119
  123. Rotman G, Shiloh Y. The ATM gene and protein, possible roles in gene surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surveys. 1997;29:285–304
  124. German J. Bloom syndrome, a Mendelian prototype of somatic mutational disease. Medicine. 1993;72:393–406
  125. German J, Ellis NA. Bloom syndrome. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 301–315
  126. German J, Roe AM, Leppert M, Ellis NA. Bloom syndrome, an analysis of cosanguinous families assigns the locus mutated to chromosome band 15q26.1. Proceedings of the Royal Academy of Sciences USA. 1994;91:6669–6673
  127. Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, et al.  The Blooms syndrome gene-product is homologous to RECQ helicases. Cell. 1995;83:655–666
  128. Watt PM, Hickson ID. Genome stability, failure to unwind causes cancer. Current Biology. 1996;6:225–267
  129. Boland CR. Hereditory nonpolyposis colorectal cancer. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 333–346
  130. Sancar A. DNA repair in humans. Annual Review of Genetics. 1995;29:69–105
  131. Tollefsbol TO, Cohen HJ. Werner's Syndrome, an underdiagnosed disorder resembling premature ageing. Age. 1984;7:75–88
  132. Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, Alisch R, et al.  Positional cloning of the Werner's syndrome gene. Science. 1996;272:258–262
  133. Fanconi G. Familial constitutional pan-myelocytopathy, Fanconi's anaemia (FA) I. Clinical aspects. Seminars in Haematology. 1967;4:233–244
  134. Auerbach AD, Buchwald M, Joenje H. Fanconi anemia. In:  Vogelstein B,  Kinzler KW editor. The genetic basis of human cancer. New York: McGraw-Hill; 1998;p. 317–332
  135. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, et al.  Expression cloning of a cDNA for the major Fanconi's anaemia gene, FAA. Nature Genetics. 1996;14:320–323
  136. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature. 1992;356:763–767
  137. Keukens F, van Vorst Vader PC, Panders AK, Vinks S, Oosterhuis JW, Kleijer WJ. Xeroderma pigmentosum, squamous cell carcinoma of the tongue. Acta Dermatology and Venereology. 1989;69:530–531
  138. Patton LL, Valdez IH. Xeroderma pigmentosum, review and report of a case. Oral Surgery, Oral Medicine and Oral Pathology. 1991;71:297–300
  139. Rey O, Lee S, Park N-H. Impaired nucleotide excision repair in UV-irradiated human oral keratinocytes immortalised with type 16 human papillomavirus genome. Oncogene. 1999;18:6997–7001
  140. Taylor M. Ataxia-telangiectasia genes and predisposition to leukemia, lymphoma and breast cancer. British Journal of Cancer. 1992;66:5–9
  141. Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genetics and Cytogenetics. 1990;46:9–19
  142. Saunders WS, Shuster M, Huang X, Gharaibeh B, Enyenihi AH, Petersen I, et al.  Chromosomal instability and cytoskeletal defects in oral cancer cells. Proceedings of the National Academy of Science USA. 2000;97:303–308
  143. Vasen HF, Offerhaus GJ, den Hartog Jager FC, Menko FH, Nagengast FM, Griffioen G, et al.  The tumour spectrum in hereditory non-polyposis colorectal cancer, a study of 24 kindreds in the Netherlands. International Journal of Cancer. 1990;46:31–34
  144. Watson P, Lynch HT. Extracolonic cancer in hereditory nonpolyposis colorectal cancer. Cancer. 1993;71:677–685
  145. Markowitz S, Wang J, Myeroff L, Parsons R, Sun LZ, Lutterbaugh J, et al.  Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336–1338
  146. Wei Q, Eicher SA, Guan Y, Cheng L, Xu J, Young LN, et al.  Reduced expression of hMLH1 and hGTBP/hMSH6, a risk factor for head and neck cancer. Cancer Epidemiology, Biomarkers and Prevention. 1998;7:309–414
  147. Goto M, Miller RW, Ishikawa I, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiology, Biomarkers and Prevention. 1996;5:239–246
  148. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anaemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genetics and Cytogenetics. 1991;51:1–12
  149. Lustig JP, Lugassy G, Neder A, Sigler E. Head and neck carcinoma in Fanconi's anaemia — report of a case and review of the literature. Oral Oncology, European Journal of Cancer. 1995;31B:68–72
  150. Koo WH, Knight LA, Ang PT. Fanconi's anaemia and recurrent squamous cell carcinoma of the oral cavity, a case report. Annals of the Academy of Medicine Singapore. 1996;25:289–292
  151. Millen FJ, Rainey MG, Hows JM, Irvine GH, Swirsky D. Oral squamous cell carcinoma after allogeneic bone marrow transplantation for Fanconi anaemia. British Journal of Haematology. 1997;99:410–414
  152. Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, et al.  Malignancies after marrow transplantation for aplastic anaemia and Fanconi's anaemia, a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392
  153. Tashiro H, Abe K, Tanioka H. Familial occurrence of cancer of the mouth. Journal of Oral and Maxillofacial Surgery. 1986;44:322–323
  154. Hara H, Ozeki S, Shiratsuchi Y, Tashiro H, Jingu K. Familial occurrence of oral cancer, report of cases. Journal of Oral Maxillofacial Surgery. 1988;46:1098–1102
  155. Ankathil R, Mathew A, Joseph F, Nair MK. Is oral cancer susceptibility inherited? Report of five oral cancer families. Oral Oncology, European Journal of Cancer. 1996;32B:63–67
  156. Ide F, Shimoyama T, Horie N. Carcinoma of the tongue in two siblings. Journal of Oral and Maxillofacial Surgery. 1999;57:66–68
  157. Copper MP, Jovanovic A, Nauta JJ, Braakhuis BJ, de Vries N, van der Waal I, et al.  Evidence for a major role of genetic factors in the etiology of head and neck squamous cell carcinoma. Archives of Otolaryngology and Head and Neck Surgery. 1995;121:157–160
  158. Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL. Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. International Journal of Cancer. 1995;63:769–773
  159. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck, retrospective case-control study. British Medical Journal. 1996;313:716–721
  160. Goldstein AM, Blot WJ, Greenberg RS, Schoenberg JB, Austin DF, Preston-Martin S, et al.  Familial risk of oral and pharyngeal cancer. Oral Oncology, European Journal of Cancer. 1994;30:319–322
  161. Jeffries S, Eeles R, Goldgar D, A'Hern R, Henk JM, Gore M. The role of genetic factors in predisposition to squamous cell carcinoma of the head and neck. British Journal of Cancer. 1999;79:865–867
  162. De Andrade M, Amos CI, Foulkes WD. Segregation analysis of squamous cell carcinoma of the head and neck, evidence of a major gene determining risk. Annals of Human Genetics. 1998;62:505–510
  163. Ankathil R, Bhattathiri NV, Francis JV, Ratheesan K, Jyothish B, Chandini R, et al.  Mutagen sensitivity as a predisposing factor in familial oral cancer. International Journal of Cancer. 1996;69:265–267
  164. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang ZF, Tobi H, et al.  Genetic susceptibility to head and neck squamous cell carcinoma. Journal of the National Cancer Institute. 1996;88:530–535
  165. Bongers V, Braakhuis BJ, Tobi H, Lubsen H, Snow GB. The relation between cancer incidence among relatives and the occurrence of multiple primary carcinomas following head and neck cancer. Cancer Epidemiology, Biomarkers and Prevention. 1996;5:595–598
  166. Kearsley JH, Bryson G, Battistuta D, Collins RJ. Prognostic importance of cellular DNA content in head and neck squamous-cell cancers. A comparison of retrospective and prospective series. International Journal of Cancer. 1991;47:31–37
  167. Roz L, Wu CL, Porter S, Scully C, Speight P, Read A, et al.  Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Research. 1996;56:1228–1231
  168. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene 06-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Research. 1999;59:793–797
  169. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, et al.  Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis. 1999;20:2125–2129
  170. Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, et al.  Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene. 1993;8:1397–1401
  171. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, et al.  In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 1993;8:2457–2467
  172. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, et al.  A p53-dependent mouse spindle checkpoint. Science. 1995;267:1353–1356
  173. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proceedings of the National Academy of Science USA. 1998;95:5166–5171
  174. Shin DM, Ro JY, Shah T, Hong WK, Hittelman WN. p53 expression and genetic instability in head and neck multistep tumorigenesis. Proceedings of the American Association of Cancer Research. 1994;35:944–951
  175. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 1993;74:813–822
  176. Evans SC, Mims B, McMasters KM, Foster CJ, deAndrade M, Amos CI, et al.  Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Human Genetics. 1998;102:681–686
  177. Warnalulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer. Journal of Pathology. 2000;190:407–409
  178. Wright EG. Inherited and inducible chromosomal instability, a fragile bridge between genome integrity mechanisms and tumourigenesis. Journal of Pathology. 1999;187:19–27
  179. Clutton SM, Townsend KMS, Walker C, Ansell JD, Wright EG. Radiation-induced genomic instability and persisting oxidative stress in bone marrow cultures. Carcinogenesis. 1996;17:1633–1639
  180. Emerit I. Reactive oxygen species, chromosome mutation and cancer, possible role of clastogenic factors in carcinogenesis. Free Radicals in Biology and Medicine. 1994;16:99–109
  181. Duell T, Lengfelder E, Fink R, Giesen R, Bauchinger M. Effect of activated oxygen species in human lymphocytes. Mutation Research. 1995;336:29–38
  182. Kadhim MA, Lorimore SA, Hepburn MD, Goodhead DT, Buckle VJ, Wright EG. Alpha-particle-induced chromosome instability in human bone marrow cells. Lancet. 1994;344:987–988
  183. de Vathaire F, Hawkins M, Campbell S, Oberlin O, Raquin MA, Schlienger JY, et al.  Second malignant neoplasms after a first cancer in childhood, temporal pattern of risk according to type of treatment. British Journal of Cancer. 1999;79:1884–1893
  184. Shillitoe EJ, May M, Patel V, Lethanakul C, Ensley JF, Strausberg RL, et al. Genome-wide analysis of oral cancer — early results from the Cancer Genome Anatomy Project. Oral Oncology. 2000;36:8–16

PII: S1368-8375(00)00055-5

Oral Oncology
Volume 37, Issue 1 , Pages 1-16 , January 2001

Article Tools